Join
Live feed
·
PRReleasevia Quantisnow
Longeveron Inc. logo

Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

ByQuantisnow·Wall Street's wire, on your screen.
LGVN· Longeveron Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LGVN (Longeveron Inc.) and more on Quantisnow.